Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ME2 | P23368 | 6/20 | 0.35 |
| ▸ | ME1 | P48163 | 6/20 | 0.35 |
| ▸ | ME3 | Q16798 | 6/20 | 0.35 |
| ▸ | SYK | P43405 | 2/20 | 0.34 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.34 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6700320 | 1.00 | ME2 (0.35) | ME2ME1ME3SYKSLC5A1 | |
| SCHEMBL6700317 | 1.00 | ME2 (0.35) | ME2ME1ME3SYKSLC5A1 | |
| SCHEMBL6702535 | 0.91 | ME2 (0.44) | ME2ME1ME3 | |
| SCHEMBL6702532 | 0.91 | ME2 (0.44) | ME2ME1ME3 | |
| SCHEMBL6702533 | 0.91 | ME2 (0.44) | ME2ME1ME3 | |
| SCHEMBL5961235 | 0.91 | ME2 (0.43) | ME2ME1ME3SIGMAR1 | |
| SCHEMBL6700021 | 0.91 | ME2 (0.43) | ME2ME1ME3SIGMAR1 | |
| SCHEMBL8338422 | 0.83 | HSD11B1 (0.39) | SYK | |
| SCHEMBL5961272 | 0.81 | ALDH1A1 (0.47) | — | |
| SCHEMBL5961270 | 0.81 | ALDH1A1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152715-A1 | Cycloalkylene amide compounds as NR2B receptor antagonists | KAWAI MAKOTO (JP) | 2004-08-05 | — | — | US | disclosed |
| WO-2004054579-A1 | 2-PYRIDYL AND 2-PYRIMIDYL CYCLOALKYLENE AMIDE COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS | PFIZER JAPAN INC. (JP) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152715-A1 | Cycloalkylene amide compounds as NR2B receptor antagonists | GRIN1, GRIN3A, GRIN2A | ME2 3006/4885ME1 2843/4885ME3 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.